Crexavibart Biosimilar - Research Grade

Product Code: ICH5455

More Information

Species Reactivity: Human

Target: Severe acute respiratory syndrome coronavirus 2

Concentration: 5mg/ml

Isotype: IgG1 - lambda2

Host: CHO Cells

product name H2: Crexavibart Biosimilar - Research Grade

Sequence: https://www.imgt.org/mAb-DB/

Buffer: ICH3002

Shipping Conditions: Blue ice

background: The SARS-CoV-2 spike protein is the determinant of viral entry and a leading antigen for neutralizing-antibody research. This antibody is an unconjugated, non-therapeutic analog of crexavibart, a human IgG1-lambda recombinant monoclonal supplied strictly for research use (RUO). It is an ultra-pure, low-endotoxin preparation meeting in vivo standards and produced in scalable milligram-to-gram quantities for heavy-usage, high-throughput virology workflows. Suitable applications include neutralization and functional assays, spike-binding characterization, in vitro screening and preclinical coronavirus-infection models, with reliable performance across lots. Built for in vivo use with low endotoxin and scalable milligram-to-gram supply, it remains a reliable choice for bulk research applications.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks